With the use of weight loss drugs on the rise, their potential risks and unintended outcomes are still being researched. However, a recent Scandinavian cohort study provides reassuring news regarding GLP1 receptor agonist treatment and thyroid cancer risk. The study found no significant association between the two, offering peace of mind to healthcare providers and patients. While further research is needed to validate these findings and explore long-term effects, this news is a step forward in understanding the safety profile of weight loss drugs. #cancerrisk#weightlossdrugs
Head of Drug Discovery Lab at City University of Hong Kong • Cancer Research • Anti-Cancer Pharmaceuticals • AI-assisted Drug Discovery • Global Public Health
#ClinicalMonday Revolutionizing Treatment for Deadly Triple-Negative Breast Cancer 🚀
Exciting news from the University of Houston! Meghana Trivedi, a professor of Pharmacy and Pharmacology, has received a $1.1 million grant from the U.S. Army Medical Research and Development Command explore the use of nebivolol, a high blood pressure medication, as a treatment for triple-negative breast cancer (TNBC).
🌟 Key points:
🔑 The goal is to provide faster, safer, and more economical treatment options.
Triple-negative breast cancer (TNBC) is an aggressive form of cancer with limited treatment options since it lacks estrogen, progesterone receptors, and excess HER2 protein.
🔑 Nebivolol shows promise in reducing TNBC cell invasion and migration, potentially inhibiting metastasis.
Nebivolol, an FDA-approved drug, is being investigated for its potential to treat TNBC, offering a cost-effective and readily available option.
🔑 GPCR-targeting drugs are under-explored in breast cancer treatment.
In preliminary studies, Trivedi identified several potential drugs targeting G protein-coupled receptors (GPCRs) for TNBC treatment. GPCRs are promising targets as they are involved in many chronic diseases and have a good safety profile. This research could significantly accelerate the availability of safe and effective treatments for TNBC patients.
🔗 For further reading on GPCR-targeting drugs, check out the study by Noor Abdulkareem et al., which screened these drugs for repositioning in breast cancer: https://lnkd.in/gg2YrP2H
Let's continue to support and celebrate innovations in cancer research that bring us closer to effective treatments and improved patient outcomes.
#BreastCancerResearch#PharmacyInnovation#CancerTreatment#HealthcareAdvances#TripleNegativeBreastCancer#GPCRTargets#DrugRepositioning
Image source: medsforless.co.uk
📢 Researchers at the ICR and The Royal Marsden NHS Foundation Trust have shown that a new 'olive oil' drug, 2-OHOA, provides benefit for patients with advanced #glioblastoma, the most common type of #BrainCancer.
One patient on the study experienced an exceptional response, with the drug working for more than three years.
🛑 The synthetic lipid restructures cancer cells' abnormal membranes, blocking their signals to grow and halting disease progression.
🌎 The drug showed promise in the early phase I/II study, and is now being trialled in a global randomised phase IIb/III study on newly diagnosed glioblastoma patients.
💬 “Glioblastoma is an incredibly difficult disease to treat. There hasn’t been an effective new treatment for this patient group in nearly two decades, so drug development urgently needs to be accelerated.” – Study lead, Dr Juanita Lopez, Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust and Reader in Early Phase Drug Development at the ICR.
Find out more about the study 👇
https://lnkd.in/enqdC8Sw#CancerResearch#DrugDevelopment#BrainTumours#BrainTumour#BrainTumourResearch#BrainTumor#BrainTumors#ClinicalTrials
In this interview, Renee Maria Saliby, MD, provides an overview of her study on whether intermediate endpoints such as time to treatment failure and time to next therapy are associated with overall survival (OS) in patients with renal cell carcinoma receiving immune checkpoint inhibitor–based treatments.
"With OS being the primary endpoint in most phase 3 trials, evaluating new drugs [has] become increasingly difficult. It's now a lengthy process and has enormous costs ... So, we were interested in looking and evaluating shorter clinical endpoints that we called intermediate endpoints and see how they associate with OS," said Dr. Saliby.
Watch the full video here 👉 https://lnkd.in/dbzedizh#JournalOfClinicalPathways#RenalCellCarcinoma#CancerCare#ImmuneCheckpointInhibitor#ClinicalTrials
Pleased to share our recent paper addressing a critical challenge in cancer treatment - Multidrug Resistance (MDR). MDR occurs when cancer cells develop resistance to multiple chemotherapy drugs, limiting treatment effectiveness.
Our study proposes an immediately implementable solution: rather than investing years and substantial funds in developing a new drug, we suggest "re-purposing" FDA-approved drugs for other diseases.
Our findings indicate that combining antidepressants (e.g., Prozac) with common chemotherapies may effectively reverse chemotherapy resistance by serving as a physical barrier, preventing the chemotherapy from exiting the cell.
I want to thank the other authors and my advisor for their invaluable contributions.
Link to the full paper: https://lnkd.in/dvRrpuRQ#cancertreatment#mdr#drugrepurposing
FDA Issues Boxed Warning For CAR-T Therapies
When a new treatment modality is approved not much clinical data is available and there are many unknowns and uncertainty.
CAR-T is a typical example.
It was reported that some cancer patients developed secondary cancers following CAR-T therapies, based on which the FDA has issued the boxed warning.
Experts feel that the benefits of CAR-T therapies far outwoutweigh the risks and should not deter oncologists from using them. The patients should be informed about the potential risks.
The MoA of the secondary cancers by CAR- T is not clear, with a few plausible explanations.
We have to wait for more data.
The Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are now useful alternatives of type 2 diabetes (T2D) management. This is because the effectively reduce A1C and weight as well as a low hypoglycemia risk.
GLP-1, is a product of the glucagon gene, and has a 30-amino-acid peptide produced in L-cells localized in the small intestine. The bioactive form of GLP-1 is released into the systemic circulation after minutes of food intake in response to the fed state, which activates specific G-protein coupled receptors, a molecule that acts as a biosensor of intracellular signaling cascade involving cyclization of Amp via adenyl cylases with 5 super family members like Glutamate, Rhodopsin, Adhesion, Frizzled/Taste2, and Secretin. Among the 5 GPCRs The GLP-1 receptor (GLP-1R) has 463 amino acids and eight hydrophobic domains. The homologues of the N-terminal extracellular hydrophobic domain expressed in tissues/organs such as the hypothalamus, lung, pancreatic islets, stomach, kidney, intestine and heart are highly preserved. GLP-1R activation leads to a rapid increase in the levels of cyclic adenosine monophosphate (AMP) and intracellular calcium followed by glucose-dependent insulin release. The GLP-1 hormone is rapidly inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4), with a half-life of only 1–2 min. Amino acid modifications in the N-terminus and at certain positions in the C-terminus are also directly involved in the receptor interaction and resistance to DPP-4 inhibition, thus prolonging its effect and half-life. GLP-1 circulates in many different forms, only some of which are biologically active. The active form of GLP-1 is GLP-1[7–36]amide, which represents a major secretory product. Once in the circulation, GLP-1[7–36]amide has a half-life of less than 2 min, being subject to rapid cleavage between positions 8 and 9 by the DPP-4 enzyme to its N-terminally truncated metabolite GLP-1[9–36]amide, which does not interact with the GLP-1R. Until recently, physiological levels of GLP-1[9–36]amide and other GLP-1 metabolites, including GLP-1[28–36]amide and GLP-1[32–36]amide, were considered to be metabolically inactive. However, different sources from recent researches have indicated that some of these metabolites have biological activity that may contribute to the pleiotropic effects of GLP-1 independently of the GLP-1 receptor. The mechanism of GLP-1RAs lies in the fact that they target fasting and Postprandial glycemia by increasing insulin and decreasing glucagon. Also GLP-1RAs reduce plasma lipids levels and enhances lower blood pressures making it beneficial to both the reduction of atherosclerosis and CVDs. GLP-1RAs drugs consist of short-acting and long-acting agents Short-acting drugs which are daily routines includes active agents like exenatide, lixisenatide and oral semaglutide. While long-acting drugs which are weekly routines includes liraglutide, semaglutide, exenatide, albiglutide and dulaglutide. This is a great work!!
#ClinicalMonday Revolutionizing Treatment for Deadly Triple-Negative Breast Cancer 🚀
Exciting news from the University of Houston! Meghana Trivedi, a professor of Pharmacy and Pharmacology, has received a $1.1 million grant from the U.S. Army Medical Research and Development Command explore the use of nebivolol, a high blood pressure medication, as a treatment for triple-negative breast cancer (TNBC).
🌟 Key points:
🔑 The goal is to provide faster, safer, and more economical treatment options.
Triple-negative breast cancer (TNBC) is an aggressive form of cancer with limited treatment options since it lacks estrogen, progesterone receptors, and excess HER2 protein.
🔑 Nebivolol shows promise in reducing TNBC cell invasion and migration, potentially inhibiting metastasis.
Nebivolol, an FDA-approved drug, is being investigated for its potential to treat TNBC, offering a cost-effective and readily available option.
🔑 GPCR-targeting drugs are under-explored in breast cancer treatment.
In preliminary studies, Trivedi identified several potential drugs targeting G protein-coupled receptors (GPCRs) for TNBC treatment. GPCRs are promising targets as they are involved in many chronic diseases and have a good safety profile. This research could significantly accelerate the availability of safe and effective treatments for TNBC patients.
🔗 For further reading on GPCR-targeting drugs, check out the study by Noor Abdulkareem et al., which screened these drugs for repositioning in breast cancer: https://lnkd.in/gg2YrP2H
Let's continue to support and celebrate innovations in cancer research that bring us closer to effective treatments and improved patient outcomes.
#BreastCancerResearch#PharmacyInnovation#CancerTreatment#HealthcareAdvances#TripleNegativeBreastCancer#GPCRTargets#DrugRepositioning
Image source: medsforless.co.uk
Drug development for cancer is hard.
Most drugs fail.
An awful lot of drugs only make incremental differences to patient's lives - e.g. an extra month or two of life with with added toxicities from the drug.
But then... just occasionally a drug like this comes along...
And makes me want to jump on a rooftop and sing with happiness 🙌
Lets celebrate these results... for patients with alk-mutated lung cancer it will CHANGE THEIR LIVES:
- after 5 years (!) progression free survival hadn't been reached. This means >50% of people hadn't had their cancer progress.
- compare this to 9months in the control (standard treatment arm) WOW
- never before has such an effect been seen in a disease like lung cancer (where survival tends to be measured in months rather than years)
We need to share more success stories like this to stimulate discussion, more research and hope for patients.
🔬 Explore the transformative journey of monoclonal antibodies (mAbs) in medical research with ProSci! These antibodies have become pivotal in researching various medical fields, including cancer, cardiovascular diseases, and autoimmune disorders.
Visit the ProSci blog for more on monoclonal antibodies and biosimilars in research: https://lnkd.in/gitUw4s7#MonoclonalAntibodies#Biosimilars
FDA and EMA Accept Vorasidenib Regulatory Submissions for the Treatment of IDH-mutant diffuse glioma
From our earliest work to identify the functional significance of IDH mutations in cancer (more than 15 years in the making!) – which led to the research and development of vorasidenib as a potential targeted therapy for IDH-mutant glioma – I am proud of the role I have had the opportunity to play in helping to advance the treatment paradigm of this difficult and hard-to-treat cancer.
Today’s acceptance and priority review of the New Drug Application by the #FDA for vorasidenib is a crucial step forward in Servier’s leadership in IDH-mutant cancers. I look forward to continuing our work as we aim to bring this new therapeutic option to patients living with IDH-mutant glioma.
Read more here: https://lnkd.in/dTVapS5V
